Diabetes Metab J.  2014 Jun;38(3):197-203. 10.4093/dmj.2014.38.3.197.

Current Status of Glycemic Control of Patients with Diabetes in Korea: The Fifth Korea National Health and Nutrition Examination Survey

• Jeon JY
• Kim DJ
• Ko SH
• Kwon HS
• Lim S
• Choi SH
• Kim CS
• An JH
• Kim NH
• Won JC
• Kim JH
• Cha BY
• Song KH
• Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association

• KMID: 2280690
• DOI: http://doi.org/10.4093/dmj.2014.38.3.197

Abstract

BACKGROUND
The Korea National Health and Nutrition Examination Survey (KNHANES) III (2005) reported that 22.9% of individuals with diabetes have a glycated hemoglobin (HbA1c) <6.5% and that 43.5% have an HbA1c <7%. We investigated the levels of glycemic control and the factors associated with glycemic control using data from the KNHANES V (2010 to 2012).
METHODS
Subjects with diabetes diagnosed by a physician or those taking antidiabetic medications were classified as individuals with known diabetes. Of 1,498 subjects aged > or =30 years with diabetes, we excluded 157 individuals who were missing HbA1c data. A total of 1,341 subjects were included in the final analysis.
RESULTS
The prevalence of known diabetes was 7.7% (n=1,498, estimated to be 2.32 million people). The proportions of well-controlled diabetes meeting a HbA1c goal of <6.5% and <7% were 27% and 45.6%, respectively. HbA1c increased as the duration of diabetes increased. HbA1c in subjects with a duration of diabetes < or =5 years was lower than in subjects with a duration >5 years. HbA1c in the group taking only oral hypoglycemic agents (OHAs) was significantly lower than that in the group administered only insulin or OHA and insulin in combination. In logistic regression analysis, a longer duration of diabetes, insulin use and the absence of chronic renal failure were associated with HbA1c levels >6.5%.
CONCLUSION
The level of adequate glycemic control was similar to but slightly improved compared with previous levels. The glycemic control of long-standing diabetes patients is more difficult even though they receive insulin treatment.

Keyword

Diabetes mellitus; Glycemic control; Korea; Korea National Health and Nutrition Examination Survey

MeSH Terms

Diabetes Mellitus
Hemoglobin A, Glycosylated
Humans
Hypoglycemic Agents
Insulin
Kidney Failure, Chronic
Korea
Logistic Models
Nutrition Surveys*
Prevalence
Hypoglycemic Agents
Insulin

Figure

• 

  Fig. 1 Study population framework. KNHANES, Korea National Health and Nutrition Examination Survey; HbA1c, glycated hemoglobin.

• 

  Fig. 2 The distribution of diabetic patients according to glycated hemoglobin (HbA1c, %) from the Korea National Health and Nutrition Examination Survey (KNHANES) III (2005) and KNHANES V (2012).

• 

  Fig. 3 The distribution of average glycated hemoglobin (HbA1c) according to the modality of diabetes treatment. OHA, oral hypoglycemic agent; DM, diabetes mellitus. aP<0.05 compared with the only OHA group.

• 

  Fig. 4 (A) The distribution of average glycated hemoglobin (HbA1c) according to the duration of diabetes. (B) The distribution of average HbA1c according to the duration of diabetes and the modality of its treatment. OHA, oral hypoglycemic agent; DM, diabetes mellitus. aP<0.05 compared with the ≤5 years group, bP<0.05 compared with the same duration OHA group.

Reference

1. Statistics Korea: Causes of death statistics 2012. updated 2013 Sep 25. Available from: http://kostat.go.kr.

2. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011; 378:169–181.

3. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287:2570–2581.

4. Jeon JY, Ko SH, Kwon HS, Kim NH, Kim JH, Kim CS, Song KH, Won JC, Lim S, Choi SH, Jang MJ, Kim Y, Oh K, Kim DJ, Cha BY. Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Prevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J. 2013; 37:349–357.

5. Choi YJ, Kim HC, Kim HM, Park SW, Kim J, Kim DJ. Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998-2005. Diabetes Care. 2009; 32:2016–2020.

6. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus of Korean Diabetes Association. Park IB, Kim J, Kim DJ, Chung CH, Oh JY, Park SW, Lee J, Choi KM, Min KW, Park JH, Son HS, Ahn CW, Kim H, Lee S, Lee IB, Choi I, Baik SH. Diabetes epidemics in Korea: reappraise nationwide survey of diabetes "diabetes in Korea 2007". Diabetes Metab J. 2013; 37:233–239.

7. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013; 368:1613–1624.

8. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Professional Practice Committee American Diabetes Association. European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006; 49:1711–1721.

9. Yu NC, Su HY, Chiou ST, Yeh MC, Yeh SW, Tzeng MS, Sheu WH. Trends of ABC control 2006-2011: a National Survey of Diabetes Health Promotion Institutes in Taiwan. Diabetes Res Clin Pract. 2013; 99:112–119.

10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–853.

11. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007; 28:187–218.

12. Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs. 2005; 65:1–13.

13. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab. 2012; 23:205–215.

14. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013; 17:819–837.

15. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010; 33:428–433.